Clinical Benefits of Achieving Deep Remission to Second-Line Therapy in Patients with Relapse/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - a Real-World Study

被引：0
|
作者：
Wierda, William G.
Gauthier, Genevieve
Meissner, Brian
Guerin, Annie
Samp, Jennifer C.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2130
引用
收藏
页数：2
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF VENETOCLAX AND RITUXIMAB COMBINATION THERAPY VERSUS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) IN COLOMBIA
    Chacon-Acevedo, K. R.
    Gamboa, O.
    Quitian Reyes, D.
    VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [32] Real-world risk of bleeding events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with BTKi
    Moslehi, Javid J.
    Wahlstrom, Svea K.
    Teschemaker, Anna
    Mackey, Rachel H.
    DeVincenzo, Diana
    Carabuena, Leslie A.
    Thompson, Samantha L.
    Gordon, Brittaney
    Rosenthal, Ning A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Real-World Effectiveness and Safety of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) in Belgium after 4 Years
    Saevels, Kirsten
    Snauwaert, Sylvia
    Vanstralen, Gaeten
    Andre, Marc
    Offner, Fritz
    Maes, Ariane
    Lahaye, Marjolein
    Janssens, Ann
    BLOOD, 2023, 142
  • [34] Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia
    Lamanna, N
    Weiss, MA
    SEMINARS IN HEMATOLOGY, 2006, 43 (02) : S44 - S49
  • [35] Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England
    Fox, Christopher P.
    Townsend, William
    Gribben, John G.
    Menne, Tobias
    Kalakonda, Nagesh
    Williams, Paula
    Toron, Farah
    Tyas, Emma
    Cooper, Miranda
    Rickards, Joshua
    Radford, John
    EJHAEM, 2024, 5 (05): : 992 - 997
  • [36] Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Danilov, Alexey V.
    Lam, Vi
    Bria, Thurlow
    Spurgeon, Stephen E.
    Park, Byung
    Orand, Kirsten
    Kittai, Adam S.
    BLOOD, 2021, 138
  • [37] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Huang, Qing
    Deering, Kathleen L.
    Harshaw, Qing
    Leslie, Lori A.
    ADVANCES IN THERAPY, 2022, 39 (07) : 3292 - 3307
  • [38] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Qing Huang
    Kathleen L. Deering
    Qing Harshaw
    Lori A. Leslie
    Advances in Therapy, 2022, 39 : 3292 - 3307
  • [39] Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
    Nie, Caiyun
    Xu, Weifeng
    Lv, Huifang
    Gao, Xiaohui
    Li, Guofeng
    Chen, Beibei
    Wang, Jianzheng
    Liu, Yingjun
    Zhao, Jing
    He, Yunduan
    Wang, Saiqi
    Chen, Xiaobing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [40] REAL-WORLD OUTCOMES OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
    Lamanna, N.
    Hurst, D.
    Latremouille-Viau, D.
    Ionescu-Ittu, R.
    Guerin, A.
    Yim, Y. M.
    Reyes, C.
    HAEMATOLOGICA, 2015, 100 : 421 - 422
12345